Megan completed her postgraduate degree in Genetics, at Stellenbosch University in South Africa, with a research focus on pharmacogenetic response in schizophrenia treatment. She moved to the UK in 2021 and worked for GSK’s Clinical Unit in Cambridge as a Clinical Research Scientist before joining the Babraham Institute.